Natera, Inc. Common Stock
NTRANatera, Inc. is a biotechnology company specializing in genetic testing and diagnostics. It develops and offers advanced cell-free DNA testing services for reproductive health, oncology, organ transplant monitoring, and rare disorders. Natera's innovative approach includes non-invasive prenatal testing (NIPT) and other laboratory-based genetic assays to help clinicians and patients make informed medical decisions.
Company News
Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.
Billionaire investor Stanley Druckenmiller has invested 30% of his portfolio in three biotech stocks: Natera, Insmed, and Teva Pharmaceutical Industries, demonstrating strong confidence in the biotech sector's potential.
The global liquid biopsy market is projected to grow from $4.03 billion in 2025 to $7.05 billion by 2030, driven by rising cancer incidence, precision medicine advancements, and technological innovations in early disease detection.
Natera's President and Chief Business Officer, John Fesko, has sold a portion of his company shares worth over $57,000 to meet tax obligations related to the vesting of restricted stock units. The transaction reflects changes in insider ownership of the company's stock.
